Cosmo Pharmaceuticals NV
SIX:COPN
US |
Alphabet Inc
NASDAQ:GOOGL
|
Media
|
|
US |
Amazon.com Inc
NASDAQ:AMZN
|
Retail
|
|
US |
Tesla Inc
NASDAQ:TSLA
|
Automobiles
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
38.9
79.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
Alphabet Inc
NASDAQ:GOOGL
|
US | |
Amazon.com Inc
NASDAQ:AMZN
|
US | |
Tesla Inc
NASDAQ:TSLA
|
US |
This alert will be permanently deleted.
Operating Margin
Cosmo Pharmaceuticals NV
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
Country | IE |
Market Cap | 1B CHF |
Operating Margin |
49%
|
Country | JP |
Market Cap | 776 550.9T JPY |
Operating Margin |
-83%
|
Country | US |
Market Cap | 710.5B USD |
Operating Margin |
35%
|
Country | UK |
Market Cap | 440.4B GBP |
Operating Margin |
3%
|
Country | DK |
Market Cap | 3.3T DKK |
Operating Margin |
44%
|
Country | US |
Market Cap | 373.5B USD |
Operating Margin |
28%
|
Country | US |
Market Cap | 251.1B USD |
Operating Margin |
34%
|
Country | CH |
Market Cap | 202.7B CHF |
Operating Margin |
32%
|
Country | CH |
Market Cap | 183.3B CHF |
Operating Margin |
31%
|
Country | UK |
Market Cap | 162.4B GBP |
Operating Margin |
21%
|
Country | IE |
Market Cap | 146B USD |
Operating Margin |
11%
|
Cosmo Pharmaceuticals NV
Glance View
Cosmo Pharmaceuticals NV engages in the development, manufacturing, and distribution of treatments for gastrointestinal diseases, endoscopy, colorectal cancer diagnosis, and colonoscopy. The company is headquartered in Dublin, Dublin and currently employs 290 full-time employees. The company went IPO on 2016-05-18. The firm develops therapies for gastrointestinal disorders. The firm's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. The company has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Cosmo Pharmaceuticals NV's most recent financial statements, the company has Operating Margin of 48.6%.